ORAM
CRSP icon

One River Asset Management’s CRISPR Therapeutics CRSP Stock Holding History

One River Asset Management’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1,962
Closed -$75.8K – 137
2024
Q4 		$75.8K Buy
1,962
+1,500
+325% +$70.8K 0.01% 209
2024
Q3 		$21.9K Buy
+462
New +$23.4K ﹤0.01% 292

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

One River Asset Management's CRSP Position: Q1 2025 in Review

One River Asset Management sold out of CRISPR Therapeutics (CRSP) in Q1 2025, closing a stake of 1,962 shares — an estimated $75.8K sold.

One River Asset Management first reported a position in CRSP in Q3 2024 and held it in 2 quarters. The position peaked at $75.8K in Q4 2024. 396 funds tracked by Wall St. Rank hold CRSP as of Q1 2025.

  • One River Asset Management reported no remaining CRISPR Therapeutics position as of Q1 2025 after selling out during the quarter.
  • One River Asset Management sold 1,962 CRISPR Therapeutics shares in Q1 2025, an estimated $75.8K.
  • One River Asset Management first reported a position in CRISPR Therapeutics in Q3 2024 and held it in 2 quarters.
  • One River Asset Management's CRISPR Therapeutics position peaked at $75.8K in Q4 2024.
  • 396 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2025.

Based on One River Asset Management's 13F filing for Q1 2025, filed 14 May 2025.